> claimed that Theranos’ products were deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters and that the company would generate more than $100 million in revenue in 2014. In truth, Theranos’ technology was never deployed by the U.S. Department of Defense and generated a little more than $100,000 in revenue from operations in 2014.
This was not even a forward-looking statement, it was an outright lie in the legal document.
One can do pretty much whatever they wish with accredited investors' money, but it has to be disclosed in the PPM.
Even if you have a line item where all the money will be spend on CEO's dog's private jet travel, accredited investors who have reviewed and signed the PPM have no legal recourse.
In Theranos case it looks like a straightforward misrepresentation of facts, which is a red flag for SEC.